BioMedNewsBreaks

WednesdayMar 03, 2021 10:36 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Isolates and Concentrates a Mustard-Derived Molecule that Acts as a Systemic, Non-Selective Bioherbicide

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced that it has isolated and concentrated an additional molecule, thiocyanate, from mustard seed. According to the update, thiocyanate is responsible for the systemic activity behind the mustard plant's natural herbicidal (weed-killer) properties and is the third molecule from mustard seed that MustGrow has isolated, extracted and concentrated. MustGrow had previously announced herbicidal proof-of-concept success without isolating thiocyanate and now expects to build on those studies with identification of this additional herbicidal mode-of-action. MustGrow has commenced greenhouse testing…

Continue Reading

TuesdayMar 02, 2021 1:44 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of $7.75 per share for $10.2 million in the private placement. Processa Pharmaceuticals secured net proceeds of $9.9 million, which will enable the company to be funded through 2023 and either expand the clinical development of PCS6422 or conduct enabling toxicology studies to advance PCS11T. “We…

Continue Reading

TuesdayMar 02, 2021 1:00 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Results of New Clinical Study Showing Value of Personalization

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled "Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study," which was published in the “Journal of Medical Internet Research (JMIR) Diabetes.” The study evaluated data from 998 people with Type 2 diabetes who used DarioHealth's digital health platform. The study focused…

Continue Reading

TuesdayMar 02, 2021 11:25 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Secures $3.6M from Exercised Warrants

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced its receipt of approximately CA$3.6M (US$2.9M) in warrant exercises since the start of 2021. “Achieving our first commercial sales in combination with a very positive outlook for 2021 has resulted in the appreciation of our share price over the last few months,” said Dr. Jack Regan, LexaGene’s CEO and founder. “The receipt of exercised warrants has significantly added to our treasury and puts us in a strong financial position for 2021.” To view the full press release, visit https://ibn.fm/tqFbl About…

Continue Reading

TuesdayMar 02, 2021 10:47 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in ‘Fireside Chat’ at Upcoming H.C. Wainwright Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its chairman and CEO, James Sapirstein, will participate in a “fireside chat” with Yi Chen, managing director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, 2021. Sapirstein will provide an overview of AzurRx’ business and clinical development programs and discuss anticipated 2021 milestones during the fireside chat scheduled to take place at 7:00 a.m. ET on Tuesday, March 9. Additionally, Sapirstein and members of the AzurRx management team will be…

Continue Reading

TuesdayMar 02, 2021 10:21 am

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Record Third Quarter Revenue, Other Q3 Highlights

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has released its interim unaudited financial results for the three and nine months ended December 31, 2020. A highlight of the report is the company’s record revenue of C$1,832,484 for the three months ended December 31, 2020 — an increase of 298% over gross revenue of C$459,982 reported in Q2. The report also noted that PlantX saw a gross margin of 20% for the same period, an increase from 5.7% in Q2. In addition, cost of sales for the company over the same period totaled C$1,465,879. The announcement noted…

Continue Reading

MondayMar 01, 2021 1:19 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March. These include the Sachs 14th Annual European Life Sciences CEO Forum taking place March 10-12, as well as the 33rd Annual Roth Conference scheduled to be held from March 15-17, 2021. The company’s president and CEO, Rodney Varner, will lead Genprex’s presentations and will be available for one-on-one meetings with investors throughout the conferences. Interested parties should visit https://ibn.fm/MUouk and https://ibn.fm/J1qLh to register. The presentations will…

Continue Reading

MondayMar 01, 2021 12:07 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Releases Update on Promotional and Marketing Activity Comments

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has provided an update to its Jan. 22, 2021, press release regarding recent promotional and investor relations. The updated comments were made at the request of IIROC and the Canadian Securities Exchange ("CSE"). The comments are specifically in regard to a newsletter published by WallStreetAlerts, on behalf of the company. In addition to the updated comments, the company reminded investors that the best source for full disclosure about the company is the company itself, as well as SEDAR…

Continue Reading

MondayMar 01, 2021 10:39 am

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Results of Annual and Special Meeting

PlantX Life (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has released results of its recent annual and special shareholder meeting. The meeting was held Feb. 26, 2021, and during the meeting, shareholders nominated and elected five board members: Quinn Field-Dyte, Lorne Rapkin, Peter Simeon, Alex Hoffman and Ralph Moxness. The company noted that incumbent director Todd Shapiro did not seek re-election at the meeting. Alex Hoffman and Ralph Moxness were elected to the board of directors for the first time. During the course of the meeting, shareholders passed all other motions on the agenda, including fixing the number of directors of…

Continue Reading

MondayMar 01, 2021 9:26 am

BioMedNewsBreaks – Grey Cloak Tech Inc. (GRCK) Changes Name, Ticker; Now Healthy Extracts Inc.

Grey Cloak Tech (OTCQB: GRCK) has announced that the company has officially changed its name to Healthy Extracts Inc. The company’s ticker will also change to OTCQB: HYEX. These changes are official today, March 1, 2021. The company is focused on the development of its proprietary natural plant-based formulations; the company is also committed to sales and distribution of cardiovascular and neuro products. Grey Cloak, now Healthy Extracts, has two subsidiaries: Ultimate Brain Nutrients, a science-based company that develops unique, plant-based, high-quality, neuro-products that increase brain health including memory, cognition, focus and neuro-energy; and BergaMet NA, a provider of nutraceutical…

Continue Reading